Panacea Biotec starts Sputnik V vaccine production in India

Panacea Biotec starts Sputnik V vaccine production in India

Panacea Biotec share rose 5% to hit an intraday high of Rs 406.10 on BSE after the domestic pharma major and Russian sovereign wealth fund announced the launch of production of the Russian Sputnik V vaccine in India.
The full-scale production of the vaccine is due to start this summer. The first batch produced at Panacea Biotec’s facilities at Baddi will be shipped to the Gamaleya Center for quality control.
Sputnik V has been registered in 66 countries globally with a total population of over 3.2 billion people. The vaccine was registered in India under the emergency use authorization procedure on April 12, 2021, and vaccination against coronavirus with the Russian vaccine started on May 14.

Efficacy of Sputnik V is 97.6% based on the analysis of data on coronavirus infection rate among those in Russia vaccinated with both components of Sputnik V from December 5, 2020, to March 31, 2021.
Sputnik V can be stored in a conventional refrigerator without any need to invest in additional cold-chain infrastructure. The price of Sputnik V is less than $10 per shot.

Disclaimer –
This document is meant for the recipient only for use as intended and not for circulation. This document should not be reproduced or copied or made available to others. The information contained herein is from the public domain or sources believed to be reliable. While reasonable care has been taken to ensure that information given is at the time believed to be fair and correct and opinions based thereupon are reasonable, due to the very nature of research it cannot be warranted or represented that it is accurate or complete and it should not be relied upon as such. Also above note is not a recommendation to Buy or SELL and is only a view based on facts and figures and we will be in no way responsible for any losses incurred by anyone who uses this information to either trade or invests securities mentioned herein.